MAI Capital Management Has $43.92 Million Holdings in Stryker Corporation $SYK

MAI Capital Management decreased its stake in shares of Stryker Corporation (NYSE:SYK) by 8.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 118,797 shares of the medical technology company’s stock after selling 10,800 shares during the period. MAI Capital Management’s holdings in Stryker were worth $43,916,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. RWA Wealth Partners LLC raised its holdings in shares of Stryker by 196.7% during the third quarter. RWA Wealth Partners LLC now owns 23,313 shares of the medical technology company’s stock valued at $8,618,000 after purchasing an additional 15,456 shares during the period. Bradley Foster & Sargent Inc. CT boosted its holdings in Stryker by 3.9% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 90,342 shares of the medical technology company’s stock worth $33,397,000 after acquiring an additional 3,371 shares in the last quarter. Vawter Financial Ltd. bought a new stake in shares of Stryker during the third quarter valued at approximately $729,000. Waddell & Associates LLC grew its position in Stryker by 8.8% in the 3rd quarter. Waddell & Associates LLC now owns 867 shares of the medical technology company’s stock valued at $320,000 after purchasing an additional 70 shares during the period. Finally, Colonial Trust Co SC increased its stake in Stryker by 5.0% during the 3rd quarter. Colonial Trust Co SC now owns 12,660 shares of the medical technology company’s stock valued at $4,680,000 after purchasing an additional 606 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.20% of the stock is currently owned by company insiders.

Stryker Trading Down 0.8%

Shares of SYK stock opened at $381.84 on Wednesday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The firm has a market cap of $146.13 billion, a P/E ratio of 45.46, a PEG ratio of 2.25 and a beta of 0.87. The company has a 50 day moving average of $361.24 and a 200-day moving average of $368.91. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same period in the prior year, the company earned $4.01 earnings per share. Stryker’s revenue was up 11.4% compared to the same quarter last year. Sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, March 31st. Stryker’s payout ratio is currently 41.90%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of analyst reports. William Blair assumed coverage on shares of Stryker in a report on Friday. They set an “outperform” rating for the company. Robert W. Baird set a $437.00 price objective on Stryker in a report on Friday, January 30th. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a report on Tuesday, January 6th. Wells Fargo & Company lifted their price objective on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Finally, Citigroup restated a “market outperform” rating on shares of Stryker in a report on Friday, January 30th. Thirteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $426.47.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.